The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study

By Garcia Esther  

CNS Drugs, Vol. 23, Iss. 7, 2009-07 ,pp. : 615-625

Adis International

Access to resources Recommend Favorite

Amisulpride vs. Risperidone in Chronic Schizophrenia - Results of a 6-month Double-blind Study

By Sechter D.   Peuskens J.   Fleurot O.   Rein W.   Lecrubier Y.   the   Amisulpride Study Group  

Neuropsychopharmacology, Vol. 27, Iss. 6, 2002-12 ,pp. : 1071-1081

Elsevier

Access to resources Recommend Favorite

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol

By Andrezina Raisa   Josiassen Richard   Marcus Ronald   Oren Dan   Manos George   Stock Elyse   Carson William   Iwamoto Taro  

Psychopharmacology, Vol. 188, Iss. 3, 2006-10 ,pp. : 281-292

Springer Publishing Company

Access to resources Recommend Favorite

Nicotine and Behavioral Markers of Risk for Schizophrenia - A Double-Blind, Placebo-Controlled, Cross-Over Study

By Depatie L.   O'Driscoll G.A.   Holahan A.-L.V.   Atkinson V.   Thavundayil J.X.   Kin N.N.Y.   Lal S.  

Neuropsychopharmacology, Vol. 27, Iss. 6, 2002-12 ,pp. : 1056-1070

Elsevier

Access to resources Recommend Favorite

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

By Poyurovsky Michael   Fuchs Camil   Pashinian Artashez   Levi Aya   Faragian Sarit   Maayan Rachel   Gil-Ad Irit  

Psychopharmacology, Vol. 192, Iss. 3, 2007-06 ,pp. : 441-448

Springer Publishing Company

Access to resources Recommend Favorite